Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMAD3 | P84022 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9428563 | 0.89 | FTO (0.56) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL9280412 | 0.84 | FTO (0.59) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL22334359 | 0.83 | FTO (0.54) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL15759875 | 0.83 | FTO (0.54) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL9427763 | 0.83 | FTO (0.54) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL9428188 | 0.82 | FTO (0.56) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL2933847 | 0.82 | FTO (0.53) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL5149281 | 0.81 | FTO (0.55) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL9427469 | 0.81 | HPGD (0.56) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL1254421 | 0.81 | FTO (0.64) | FTOMAPTHPGDMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0606804-B1 | Marker for neurotensin receptor | MARTINEX R & D INC (CA) | 2001-10-04 | — | — | EP | claimed |
| EP-0069450-B1 | LABELLED VITAMIN B12 DERIVATIVES, THEIR PREPARATION AND USE | TECHNICON INSTRUMENTS CORPORATION (a New York corporation) (US) | 1985-04-10 | — | — | EP | claimed |
| US-11604185-B2 | Methods for detection of botulinum neurotoxin | CITY OF HOPE (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210255174-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | CITY OF HOPE (US) | 2021-08-19 | — | — | US | disclosed |
| US-10775366-B2 | Substrates for detection of botulinum neurotoxin | CITY OF HOPE (US) | 2020-09-15 | — | — | US | disclosed |
| US-20170153228-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-01 | — | — | US | disclosed |
| US-9562903-B2 | Methods for detection of botulinum neurotoxin | CITY OF HOPE (US) | 2017-02-07 | — | — | US | disclosed |
| US-20140287433-A1 | MEANS AND METHODS FOR DETERMINING CLOSTRIDIAL NEUROTOXINS | ETH Zürich (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140235490-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | CITY OF HOPE (US) | 2014-08-21 | — | — | US | disclosed |
| US-8753831-B2 | Methods for detection of botulinum neurotoxin | CITY OF HOPE (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2734635-A1 | MEANS AND METHODS FOR DETERMINING CLOSTRIDIAL NEUROTOXINS | ETH Zürich (CH) | 2014-05-28 | — | — | EP | disclosed |
| US-8067192-B2 | Methods for detection of botulinum neurotoxin | CITY OF HOPE (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
| US-7718680-B2 | Inhibition of lethal factor protease activity from anthrax toxin | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090176259-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-09 | — | — | US | disclosed |
| US-20090082266-A1 | CONJUGATE OF WATER-SOLUBLE HYALURONIC ACID MODIFICATION PRODUCT WITH GLP-A ANALOGUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-02-07 | — | — | US | disclosed |
| EP-1857467-A1 | CONJUGATE OF WATER-SOLUBLE MODIFIED HYALURONIC ACID AND GLP-1 ANALOGUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-6630295-B2 | Monitoring molecular weight adjustment in ionic compound; obtain chemical intermediates, incubate with fluorescent dyes, monitor fluorescence polarization to detect molecular weight adjustment | INSIGHT STRATEGY & MARKETING LTD. (IL) | 2003-10-07 | — | — | US | disclosed |
| US-20020115071-A1 | High throughput assay for monitoring polycation or polyanion molecular weight, degradation or synthesis | INSIGHT STRATEGY & MARKETING LTD. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11604185-B2 | Methods for detection of botulinum neurotoxin | ANTXR2, INHA, PRSS12 | FTO 3566/4885MAPT 3282/4885HPGD 2615/4885 |
| US-20090082266-A1 | CONJUGATE OF WATER-SOLUBLE HYALURONIC ACID MODIFICATION PRODUCT WITH GLP-A ANALOGUE | GLP1R, IAPP, GIPR | FTO 1132/4885MAPT 3502/4885HPGD 418/4885 |
| US-20210255174-A1 | METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN | ANTXR2, INHA, PRSS12 | FTO 3566/4885MAPT 3282/4885HPGD 2615/4885 |
| US-10775366-B2 | Substrates for detection of botulinum neurotoxin | ANTXR2, INHA, PRSS12 | FTO 3330/4885MAPT 3233/4885HPGD 2573/4885 |
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | APAF1, ANTXR2, SERPINB1 | FTO 4851/4885MAPT 4512/4885HPGD 1670/4885 |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | APAF1, ANTXR2, SERPINB1 | FTO 4851/4885MAPT 4512/4885HPGD 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.